April 22, 2024

Information about Naloxone and Nalmefene

The agency continues to advance the FDA Overdose Prevention Framework and take actionable steps that encourage harm reduction by supporting the availability, accessibility, and development of […]
April 20, 2024

PDUFA Performance Reports

On September 30, 2022, the President signed into law the FDA User Fee Reauthorization Act of 2022 (FUFRA), which included the reauthorization of the Prescription Drug […]
April 19, 2024

FDA Roundup: April 19, 2024

For Immediate Release: April 19, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0